Crossmark

Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary

Crossref DOI link: https://doi.org/10.1007/s00277-023-05354-8

Published Online: 2023-07-10

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Husi, Kata

Szabó, Roxána

Pinczés, László Imre

Földeák, Dóra

Dudley, Réka

Szomor, Árpád

Koller, Beáta

Gopcsa, László

Illés, Árpád

Miltényi, Zsófia https://orcid.org/0000-0003-3507-9997
Funding

Funding for this research was provided by:

University of Debrecen
License Information

Text and Data Mining valid from 2023-07-10

Version of Record valid from 2023-07-10
More Information

Article History

Received: 10 March 2023

Accepted: 30 June 2023

First Online: 10 July 2023

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below